[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc (SLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here

The biotechnology sector has long rewarded companies that can translate early clinical promise into late-stage validation, and nowhere is that dynamic more pronounced than in oncology. Acute myeloid leukemia (AML) remains one of the most challenging cancers to treat, with limited durable options for patients who relapse after standard therapy. 

That unmet need has made AML-focused immunotherapy a magnet for both strategic pharmaceutical partnerships and investor capital willing to underwrite clinical-stage risk in exchange for outsized upside potential. SELLAS Life Sciences Group, Inc. (SLS) sits squarely within this high-stakes corner of the market. 

The company’s pipeline centers on galinpepimut-S (GPS), a...

Fundamentals

See More
  • Market Capitalization, $K 2,693,960
  • Shares Outstanding, K 201,946
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,860 K
  • EBIT $ -35 M
  • EBITDA $ -35 M
  • 60-Month Beta 2.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 18.87

Options Overview Details

View History
  • Implied Volatility 193.96% (-9.27%)
  • Historical Volatility 98.08%
  • IV Percentile 81%
  • IV Rank 59.06%
  • IV High 260.74% on 07/23/26
  • IV Low 97.63% on 12/17/25
  • Expected Move (DTE 3) 0.89 (6.94%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 25,027
  • Volume Avg (30-Day) 41,284
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 1,008,161
  • Open Int (30-Day) 979,251
  • Expected Range 11.97 to 13.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) +1,427,242.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.80 +32.14%
on 08/03/26
15.67 -17.36%
on 08/21/26
+2.94 (+29.37%)
since 07/31/26
3-Month
7.07 +83.17%
on 06/11/26
15.88 -18.43%
on 06/30/26
+3.88 (+42.78%)
since 06/01/26
52-Week
1.39 +831.65%
on 12/02/25
15.88 -18.43%
on 06/30/26
+11.03 (+574.48%)
since 08/29/25

Most Recent Stories

More News
Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here

Sellas is gaining Wall Street’s attention as clinical progress, upcoming catalysts, and positive analyst sentiment strengthen the case for further upside.

SLS : 12.96 (-2.85%)
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

 - Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80th Event - - 28 Patients...

SLS : 12.96 (-2.85%)
SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

 - Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - - 28 Patients Enrolled in Phase 2 Trial of SLS009 in...

SLS : 12.96 (-2.85%)
PepsiCo’s $22M Ratio Call Diagonal Spread Signals Big Bullish Bet Ahead of Q3 Earnings

PepsiCo’s unusual options activity yesterday points to a $22 million bet on a ratio call diagonal spread with a breakeven near $155.50, targeting a rebound ahead of PepsiCo's Q3 earnings report.

MSFT : 500.77 (-1.29%)
KO : 88.17 (-0.56%)
BRK.B : 504.49 (+0.09%)
INFY : 12.01 (-0.41%)
PEP : 139.88 (-0.33%)
SLS : 12.96 (-2.85%)
This Little-Known Stock Has Surged 550% in the Past Year

SELLAS Life Sciences (SLS) has surged 550% in the past year, driven by technical momentum and speculative trading. SLS currently has no revenue, with all products in development or clinical trials, making...

SLS : 12.96 (-2.85%)
SELLAS Life Sciences to Participate in Upcoming Investor Conferences

NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development...

SLS : 12.96 (-2.85%)
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78 Events have Occurred in the Trial as of May 11,...

SLS : 12.96 (-2.85%)
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company that 78...

SLS : 12.96 (-2.85%)
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – – First Patient Dosed in Phase 2 Trial...

SLS : 12.96 (-2.85%)
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events – ...

SLS : 12.96 (-2.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present...

See More

Key Turning Points

3rd Resistance Point 14.42
2nd Resistance Point 14.05
1st Resistance Point 13.69
Last Price 12.96
1st Support Level 12.96
2nd Support Level 12.59
3rd Support Level 12.23

See More

52-Week High 15.88
Last Price 12.96
Fibonacci 61.8% 10.34
Fibonacci 50% 8.63
Fibonacci 38.2% 6.92
52-Week Low 1.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.